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Abstract 
Background: Globally, there is a consensus to end the HIV/AIDS epidemic by 2030, and one of the strategies to 
achieve this target is that 90% of people living with HIV should know their HIV status. Even if there is strong evidence 
of clients’ preference for testing in the community, HIV voluntary counseling and testing (VCT) continue to be under-
taken predominantly in health facilities. Hence, empirical cost-effectiveness evidence about different HIV counseling 
and testing models is essential to inform whether such community-based testing are justifiable compared with addi-
tional resources required. Therefore, the purpose of this study was to compare the cost-effectiveness of facility-based, 
stand-alone and mobile-based HIV voluntary counseling and testing methods in Addis Ababa, Ethiopia.
Methods: Annual economic costs of counseling and testing methods were collected from the providers’ perspective 
from July 2016 to June 2017. Ingredients based bottom-up costing approach was applied. The effectiveness of the 
interventions was measured in terms of the number of HIV seropositive clients identified. Decision tree modeling was 
built using TreeAge Pro 2018 software, and one-way and probabilistic sensitivity analyses were conducted by varying 
HIV positivity rate, costs, and probabilities.
Results: The cost of test per client for facility-based, stand-alone and mobile-based VCT was $5.06, $6.55 and $3.35, 
respectively. The unit costs of test per HIV seropositive client for the corresponding models were $158.82, $150.97 and 
$135.82, respectively. Of the three models, stand-alone-based VCT was extendedly dominated. Mobile-based VCT 
costs, an additional cost of USD 239 for every HIV positive client identified when compared to facility-based VCT.
Conclusion: Using a mobile-based VCT approach costs less than both the facility-based and stand-alone 
approaches, in terms of both unit cost per tested individual and unit cost per HIV seropositive cases identified. The 
stand-alone VCT approach was not cost-effective compared to facility-based and mobile-based VCT. The incremental 
cost-effectiveness ratio for mobile-based VCT compared with facility-based VCT was USD 239 per HIV positive case.
Keywords: Ingredients costing, Decision tree modeling, Reciprocal cost allocation, Cost-effectiveness analysis, VCT 
models
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Background
HIV is one of the most devastating global epidemics in 
human history. Since the beginning of the epidemic, 
about 78 million people had been infected, and more 
than 35 million people have died. Globally, in 2016, about 
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42 million people are living with HIV/AIDS [1], out of 
which, 19.4 million are living in Eastern and Southern 
African regions. The number of new HIV infections in 
2016 was 1.8 million worldwide, and sub-Saharan Afri-
can accounts for three-quarters of the new infections and 
deaths [2]. In Ethiopia, about 27,200 new HIV infections 
happened in 2016, and the incidence of infection in the 
urban areas (6.8%) is many times higher than in rural 
areas (0.7%) [3].
UNAIDS’s 90-90-90 goal sets new targets. This aim of 
this goal is to detect 90% of people living with HIV by 
2020, to treat and retain 90% of those who are identi-
fied as HIV positive on antiretroviral therapy (ART), to 
reduce the viral load to an undetectable level for 90% of 
those on ART [4]. Evidence shows that if the 90-90-90 
goal is achieved by 2020, it will help end the epidemic 
by 2030, which will have profound economic and health 
benefits [5]. To ensure timely access to effective HIV 
treatment and reinforce the prevention of new infections, 
the creation of awareness of HIV status through HIV vol-
untary counseling and testing (VCT) is a crucial activity 
[6].
Among women and adults between the ages of 15–49, 
the proportion of people who have been tested for HIV is 
about 70% globally and 50% in Africa [7]. Similarly, more 
than half of the Ethiopian population, in general, and 
27% of people living in the capital city, Addis Ababa, had 
never been tested, and only 67% of HIV seropositive indi-
viduals know their HIV status [8]. However, the target set 
by UNAIDS is to detect 90% of HIV positive individuals 
by the end of 2020. To reach this ambitious goal, a cost-
effective VCT model that identifies more HIV positive 
individuals is required.
In Ethiopia, the current HIV testing and counseling 
(HTC) service delivery models are classified into four: 
integrated facility-based HTC services (Facility-based 
VCT and provider-initiated testing and counseling), 
Standalone VCT, Outreach, and mobile VCT, and Work-
place HTC service. The services are generally established 
on community-based and facility-based HIV testing and 
counseling approaches [9]. Facility-based VCT is HIV 
testing and counseling conducted in health facilities 
(hospitals, health centers, and private clinics) initiated 
by the clients. Stand-alone-based VCT is a type of HIV 
counseling and testing service delivery model conducted 
outside hospitals and health centers as a fixed VCT oper-
ating on its own. Mobile-based VCT is a type of com-
munity-based HCT conducted by setting up a mobile 
van or container to provide HIV counseling and testing 
services in a community’s central area. The clients initi-
ate all three testing strategies. Their difference is in the 
place of service delivery. Facility and stand-alone-based 
VCT are services provided at specific places, whereas 
mobile-based VCT provides services in the community’s 
central area. The facility, stand-alone, and mobile-based 
VCT models followed standardized procedures for ser-
vice delivery. VCT is free, voluntary, and confidential and 
is delivered by trained counselors after a serial algorithm 
of rapid HIV antibody tests with a finger-prick blood 
sample collection [10].
The unit cost per client tested for HIV at the facility-
based VCT is USD 5 in Malawi, and USD 4 in Zambia, 
USD 9 in Zimbabwe [11], and ranges from USD 5.05 to 
16 in Kenya [12]. The cost per client tested for HIV for 
the stand-alone-based VCT is USD 20 in a systematic 
review of low and middle-income countries [13], USD 51 
in South Africa [14], USD 19 in Uganda [15], USD 58 in 
Vietnam [16], and USD 60 in Namibia [17]. The cost per 
client tested for HIV in a mobile-based VCT is USD 25 
South Africa, USD 15 in Kenya and USD 60 in Namibia 
[17–19]. A systematic review conducted also estimated 
the cost per client test through mobile-based VCT to be 
USD 60 [20].
Some studies show that, although the costs tend to be 
higher than facility-based HTC services, mobile-based 
HCT is better to reach HIV infected individuals earlier 
in the disease progression [21–23]. Mobile-based HCT 
detects more first-time testers and HIV positive indi-
viduals with high CD4 cell counts. Community-based 
HTC with mobilization and enhanced linkage to care 
can overcome barriers to HIV testing and linkage to care, 
achieving widespread coverage of testing and antiretro-
viral therapy [24, 25]. Community-based HTC also relies 
less heavily on existing infrastructure, allowing easier 
scale-up [20]. Currently, the VCT service continues to be 
undertaken predominantly in health facilities [26]. How-
ever, evidence shows that less time and costs are spent by 
the people who use mobile-based VCT than the facility-
based VCT [27, 28]. Besides, clients prefer more to be 
tested in the community than in health facilities [29, 30].
The choice of different HIV testing and counseling 
models should be based on evidence about the total 
costs of the services and the total health benefit accrued 
from each of the strategies. The costs and the health ben-
efit are affected by different factors, such as physical and 
financial accessibility of the services, HIV prevalence, 
the country’s economic status, the skill of counselors, 
the degree of emphasis placed on careful and intensive 
counseling, the number attending relative to the capacity 
of the service, the type of test and number of tests [13, 
31, 32]. Country-level cost-effectiveness evidence about 
different HIV counseling and testing models are impor-
tant to inform priority-making decisions. However, none 
of the studies conducted in Ethiopia tried to investigate 
this. Therefore, this study aimed to compare the cost 
and cost-effectiveness of facility-based, stand-alone and 
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This study was conducted in Addis Ababa, Ethiopia’s 
capital city, with a total population of about 3.4 million. 
There are 11 hospitals, 97 health centers, one stand-alone 
VCT clinics, and 15 mobile VCT service sites in the city. 
The city has the highest concentrations of HIV/AIDS 
cases in the country, with an estimated prevalence of 
4.9% and contributes 16% of the country’s new infection 
in 2016 [3].
Sampling and data collection
Primary cost data were collected from July 2016 to June 
2017 from selected facilities in Addis Ababa city. For 
facility-based VCT costing, from 97 health centers pro-
viding VCT service in the city, only ten health centers 
were included due to budget constraints. One health 
center was randomly included from each sub-city, and 
only facility-based VCT is considered and not the pro-
vider-initiated HTC. For stand-alone and mobile-based 
testing, a center-specific costing approach was applied. In 
Addis Ababa, there is only one stand-alone VCT testing 
facility, and we include that facility in this study. There 
are 15 mobile-based VCT centers in the city, and all of 
them were included in the costing exercise. Data for the 
stand-alone and mobile testing sites were collected from 
the AHF.
Costing approach
This study uses an ingredient costing approach to deter-
mine costs whereby actions to be taken under interven-
tion are listed, specific resources needed to implement 
the intervention are described, and costs are assigned to 
all the resources based on opportunity costs used for the 
intervention [33, 34]. It allows analysts from one country 
to assess if costs collected in another country can be used 
or modified to their settings [35]. However, the use of the 
ingredients costing approach makes it necessary to deter-
mine overhead costs. The complementary cost allocation 
approach was used to estimate the overhead costs. It fully 
recognizes complementary services provided among all 
support service centers and allocate costs between the 
support service centers [36]. All the costs were adjusted 
for inflation using a consumer price index of the year 
2019 as a base year cost. All costs were expressed in 2019 
US Dollars.
Capital costs include buildings, equipment, and vehi-
cles, which were annualized using a discount rate of 5% 
with an assumed lifespan of 30  years for vehicles and 
5  years for equipment [32, 37]. Because some buildings 
are older than their expected year of service, others are 
rented and recently built; the rental cost of a building was 
considered an economic cost to have the same cost com-
parison across the interventions. Recurrent costs include 
personnel, gloves and test kits, other supplies, vehicle 
operation and maintenance, and building operation and 
maintenance. About 10% of the annual rent cost was used 
as the annual cost of building operation and maintenance 
[32] (Table 1).
Cost allocation method
The service sites were health centers (facility-based 
VCT), stand-alone VCT clinics, and mobile VCT sites. 
The service sites were divided into the care service 
center (VCT center) and support service center. Sup-
port service centers were divided into ancillary and site 
management. The ancillary support service centers 
include the cleaning and transportation sections. The 
site management includes site administration, security, 
finance, human resources, disease prevention, medical 
Table 1 Recurrent and capital cost components of the VCT service costing
Recurrent cost Allocation base Cost data Method of data collection and data source
Personnel Time worked Total payment for full-time staff, part-time 
staff, and volunteers
Review of annual payroll, and reports and interview
Supplies Weight/volume Replacement value Review of activity, reports, and interview
Operation and 
maintenance of a 
vehicle
Time used and volume Replacement value Review of reports and interview
Capital cost Working life year (source)
Buildings Space used Rental value Interview
Equipment Time used Replacement value and annualization [32, 37] Review of fixed assets list and interview
Vehicles Time used Replacement value and annualization [32, 37] Gov’t contracts, supply record from NGO, local dealers
Others Actual value
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director, counselor coordinator, country program direc-
tor, accountant, and data clerk.
All the capital and recurrent inputs of the support ser-
vice centers were identified, measured, and valued. The 
total cost for each support service center was then cal-
culated. Costs were allocated among the support service 
centers using the reciprocal cost allocation method. We 
took into account the number of staff per service out-
put of the support service centers as the allocation base. 
After allocating the costs within the support service cent-
ers, allocating the costs from support service centers to 
the care service centers (VCT) was made.
The cost allocated from the support service center is 
added to the VCT center. Since the resource use (e.g., 
counselor’s time and test kits) to identify HIV-positive 
and HIV-negative client is different, we used the time it 
takes for testing and the number of tested and positive 
individuals as the allocation base to estimate the cost 
for tested and HIV positive clients. The total amount of 
time per client was estimated by interviewing counse-
lors on the time they spent to identify HIV positive and 
HIV negative test result, pre-test counseling time, testing 
time, and post-test counseling time with the patients. The 
number of tested clients and HIV positive clients were 
collected from the facility record. The unit costs and the 
total costs of the VCT service site was then calculated 
[38, 39].
Overall, the cost analysis included in this study were 
unit cost per positive-case, cost per test, the total capi-
tal cost per tested-case, recurrent cost per tested-case. 
Furthermore, descriptive analysis was performed by cal-
culating the number and percentage of clients tested for 
HIV and HIV positive clients by age and sex for the three 
HIV testing approaches.
Cost‑effectiveness model
A decision tree model was built using TreeAge Pro 2018 
software [40]. The decision tree model is the model’s 
choice when an event happens in a short period and does 
not happen repeatedly. The model follows a series of 
steps to construct a tree structure under uncertainty for 
alternative options and select the least expected cost per 
effect as the best alternative. A cost-effectiveness ratio 
was calculated for each of the VCT approaches using cost 
per HIV seropositive client tested as payoffs. The struc-
ture of the model of the cost-effectiveness study is pre-
sented in Fig. 1.
The decision to be addressed is “which VCT model is 
cost-effective in diagnosing HIV positive client among 
facility-based VCT, Stand-alone VCT and Mobile-
based VCT,” expressed on the decision node at the start 
of the tree. The range of possible pathways that char-
acterize the three testing strategies is explained on the 
chance nodes following the decision pathways. The 
pathways are built up through a series of branches rep-
resenting the natural process of the testing event. Here 
the events are HIV testing, positivity rate, and test pos-
itivity. Branch probabilities are the likelihood of events 
issuing from a chance node and representing the possi-
ble events happening in the testing process at that point 
in the tree. Here the probabilities are the probability 
of being tested, the probability of being HIV positive, 
and test sensitivity. The combination of the different 
branches in the tree determines a series of pathways 
along which the HIV testing and counseling can pass 
in the tree. These pathways are mutually exclusive and 
exhaustive. So, probabilities at a pathway should sum 
to 100%. The analysis was performed through chance 
nodes showing uncertain previous events moving from 
left to right using conditional probabilities. Expected 
values in cost and effectiveness are then calculated. 
The three testing strategies’ expected cost is calculated 
by weighing each pathway cost by its respective prob-
ability and then summing across all the pathways. This 
decision model uses the probability of identifying HIV 
positive clients as the relevant measure of effect in the 
CEA (i.e., the probability of diagnosing HIV). In terms 
of expected effectiveness, this is equivalent to giving 
HIV diagnosis though testing the value = 1 and all other 
pathways, the value = 0 (i.e., HIV diagnosis = 1 and No 
diagnosis = 0). Following this, the expected effect is cal-
culated by weighing each pathway’s effectiveness by its 
respective probabilities and then summing across all 
the pathways.
The input parameters presented in Table 2 for the tree 
structure are taken from literature and primary data 
from the health facilities. For example, the probability 
of being tested at a VCT site is calculated by dividing 
the number of people tested at a site by the estimated 
population of age above fifteen to be served under that 
service site. The urban health center serves 40,000 peo-
ple, and the population age group of above 15 is around 
57% of the total population [41]. The number of people 
tested for HIV in 2016, using each of the testing mod-
els, was divided by mid-year total population above 
15  years of age. HIV disease prevalence was used to 
calculate the probability of being positive. To estimate 
the HIV positivity rate at the three testing modalities, 
we divided the number of HIV positive identified in a 
year by the total number of people tested for HIV for 
each testing modalities. Therefore, HIV positivity rates 
are different for each modality as the number of HIV 
positive individuals identified, and numbers tested for 
HIV are different for the three modalities. Finally, test 
sensitivity and test specificity were used for the actual 
status of the client.
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Model assumption
Since there was no information on the number of peo-
ple expected to be served under a single stand-alone 
and mobile VCT site, a common denominator of the 
catchment population based on the Ethiopian health 
care delivery system of the facility-based VCT (health 
center) for stand-alone and mobile-based VCT was 
used.
Sensitivity analysis
Two types of sensitivity analyses were performed to deal 
with uncertainties in this study. First, a one-way sensitiv-
ity analysis was done using a tornado diagram for the low 
and high values of costs, probabilities, test-sensitivity, 
test-specificity and prevalence from the base case [43]. 
One-way sensitivity analysis was also conducted on HIV 
positivity rate, considering that HIV positivity rate is 
Fig. 1 Model structure of the cost-effectiveness study
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likely to change over time. The lower and the higher value 
choice were made considering the clinical and economic 
feasibility of the range concerning the setting. Second, 
probabilistic sensitivity analysis (PSA) was conducted to 
distribute the parameters used for a one-way sensitivity 
analysis. PSA uses a distribution rather than a predeter-
mined value for each parameter. Gamma and beta distri-
butions were used for cost and probabilities, respectively. 
The distribution for cost was varied by reviewing the cost 
of supply agencies from whom government health cent-
ers are expected to buy and allow variation of salary by 
looking at the least and highest salaries of the health 
facilities. Therefore, a 20% variation from the mean cost 
was allowed for the three models’ costs.
Results
Demographic characteristics of clients
The number of clients tested for HIV from July 2016 to 
June 2017 in the ten health centers, one stand-alone and 
15 mobile sites was 12,913, 3155 and 128,199, respec-
tively. The proportion of women tested for HIV was 
higher in the health centers (59%) and less in the stand-
alone clinic (47%) and mobile sites (34%) than men. Of 
the clients tested, a vast majority were in the age group of 
25–49 (Table 3).
Although a smaller number of women were tested in 
both stand-alone and mobile VCT sites than men, the 
proportion of positive cases was higher among females 
than in males. For example, from the total people tested 
and HIV positive cases, the proportion of females testing 
positive was 68%, 61%, and 58% in facility-based, stand-
alone and mobile-based sites, respectively (Table 4). The 
proportion of females tested for HIV is higher in health 
centers than stand-alone and mobile-based testing for 
the age group 25-49. Female aged between 25 and 49 has 
a higher HIV positivity rate than male in the three testing 
approaches.
Costs per client tested
The cost per client test for facility-based VCT was USD 
5.06 (SD 4.92, 5.21). Out of this, the cost of personnel 
account for 49% and the glove and test kit contribute to 
30% of the cost. The cost of building, other supplies and 
equipment contributed to the rest of the cost. The cost 
per client tested for stand-alone VCT was USD 6.55. 
The cost of personnel and glove and test kit and build-
ing contribute to 54.4%, 22.4%, and 17.6% of the cost. 
Other supplies and equipment contribute to the remain-
ing cost. The cost per client tested for mobile-based VCT 
was USD 3.35. Out of this, the cost of the glove and test 
kit, personnel, and vehicle rent contributes to 59%, 35.3%, 
Table 2 Input parameters of the cost-effectiveness model
Input parameters Base value Low value High value SD Distribution Data sources
Cost of positive for facility-based VCT 158.82 127.06 190.59 10.00 Gama Primary
Cost of negative for facility-based VCT 4.95 3.96 5.94 0.49 Gama Primary
Cost of positive for stand-alone VCT 150.97 120.78 181.17 10.00 Gama Primary
Cost of negative for stand-alone VCT 6.39 5.11 7.67 0.64 Gama Primary
Cost of positive for mobile-based VCT 135.53 108.42 162.63 10.00 Gama Primary
Cost of negative for mobile-based VCT 3.28 2.63 3.9 0.32 Gama Primary
Probability of being tested at facility-based VCT 0.050 0.030 0.100 0.006 Beta Primary
Probability of being tested at stand-alone VCT 0.120 0.080 0.160 0.020 Beta Primary
Probability of being tested at mobile-based VCT 0.340 0.200 0.400 0.080 Beta Primary
Test sensitivity 0.997 0.993 1.000 0.001 Beta [42]
Test specificity 0.992 0.990 1.000 0.002 Beta [42]
HIV positivity rate: facility VCT 0.032 0.022 0.042 0.001 Beta Primary
HIV positivity rate: stand-alone VCT 0.043 0.033 0.053 0.001 Beta Primary
HIV positivity rate: mobile-based VCT 0.025 0.015 0.035 0.001 Beta Primary
Table 3 Clients who received VCT service from  July 2016 
to June 2017
Characteristics Facility‑based Stand‑alone Mobile‑based
Sex
 Male (positive) 5347 (134) 1685 (54) 85,668 (1389)
 Female (positive) 7566 (278) 1470 (83) 42,214 (1780)
Age
 15–19 1897 430 10,267
 20–24 3734 655 40,398
 25–49 6468 1921 72,524
 50+ 814 149 4693
Total (positive) 12,913 (412) 3155 (137) 128,199 (3169)
Positivity rate 3.1% 4.3% 2.4%
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and 9% of the cost, respectively. The building, other sup-
plies, and equipment contribute to the remaining cost.
Costs per HIV seropositive client
The costs per HIV seropositive for facility-based, stand-
alone, and mobile-based VCT are presented in Table  5. 
The cost per test for HIV seropositive clients was USD 
158.82 for facility-based VCT, USD 150.97 for stand-
alone, and USD 135.52 for mobile-based VCT. Out of 
this, the cost of personnel and glove and test kit accounts 
for most of the costs. The contribution of cost from the 
support service center and cost from a direct service 
center to a single site for the three VCT models is pre-
sented in Table 5. The cost of the support service center 
was the highest for mobile-based VCT, followed by 
stand-alone and facility-based VCT.
Cost‑effectiveness ratio
The expected cost and effectiveness was calculated to 
determine the most cost-effective VCT model. Stand-
alone VCT is extendedly dominated by mobile and facil-
ity-based VCT since the ICER of stand-alone-based VCT 
compared to facility-based VCT is higher than the next 
effective (mobile-based VCT) strategy. After excluding 
the extendedly dominated stand-alone-based VCT, the 
ICER of facility-based and mobile-based VCT was recal-
culated. The incremental cost-effectiveness ratio of the 
mobile-based VCT was USD 239 for the identification 
Table 4 Percent of tested and HIV positive clients by age from July 2016 to June 2017
Characteristics Facility‑based Stand‑alone Mobile‑based
Male Female Male Female Male Female
Tested clients (%) by age group
 15–19 2.60 7.50 3.60 10.00 3.90 4.10
 20–24 14.40 17.50 9.30 11.50 20.20 11.30
 25–49 24.40 27.60 36.80 24.10 39.70 16.90
 50+ 2.70 3.20 3.80 1.00 3.00 0.70
Positive clients (%) by age group
 15–19 1.00 3.20 2.00 7.00 0.60 1.30
 20–24 1.60 8.60 7.00 7.00 3.00 7.00
 25–49 24.60 53.90 41.00 64.00 33.20 43.70
 50+ 4.40 2.80 4.00 5.00 7.10 4.10
Table 5 Total and unit cost of tested and test-positive by VCT types per HIV testing facility
Service site Support center VCT center Total cost Tested clients Testing unit 
cost
Positive clients Positive unit cost
Facility-based 1285.03 64,149.83 65,434.86 1291 5.06 41.20 158.82
Stand-alone 3633.09 17,050.24 20,683.34 3155 6.55 137.00 150.97
Mobile-based 3006.78 25,625.62 28,632.40 8546 3.35 211.26 135.52
Table 6 Incremental cost-effectiveness ratios of facility-based, stand-alone, and mobile-based VCT
ACER average cost-effectiveness ratio
Strategy Cost Inc. cost Effectiveness Inc. effectiveness ICER ACER
Excluding dominated
 Facility-based VCT 0.53 0.002 269.87
 Mobile-based VCT 2.72 2.19 0.011 0.009 239.01 244.51
All
 Facility-based VCT 0.53 0.00 0.002 0.000 0.00 269.87
 Stand-alone-based VCT 1.67 1.14 0.006 0.004 279.34 276.24
 Mobile-based VCT 2.72 1.05 0.011 0.005 206.50 244.51
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of additional HIV seropositive clients when compared to 
facility-based VCT (Table 6).
Sensitivity analysis
One-way sensitivity analysis using a tornado diagram 
with a least-likely and highly likely value of the selected 
variables is presented in Fig. 2. The tornado diagram indi-
cates that the cost of a positive test at mobile-based VCT 
had the highest impact on the incremental cost-effective-
ness ratio. Although the ICER is changing for lower and 
higher values of the cost of positive test at mobile-based 
VCT, the ICER showed around 17% change (from USD 
158 to 225 per HIV seropositive client identified). The 
ICER was less sensitive to change in most of the other 
variables in general.
As the cost of identifying HIV positive individuals 
increase at mobile-based VCT, the ICER also increases 
and vice versa. Therefore, mobile testing may be a more 
cost-effective approach in the high prevalence area 
(Fig. 3).
In Figs.  4 and 5, we present the probabilistic sensitiv-
ity analysis using the cost-effectiveness scatter plot and 
acceptability curve. The cost-effectiveness scatters plot 
indicates that there is less variability across both cost and 
effectiveness of facility-based VCT, while the variability 
in the other two options was vast in both cost and effec-
tiveness dimension (Fig. 4).
The cost-effectiveness acceptability curves (CEAC) 
indicates the probability of being cost-effective at differ-
ent levels of willingness to pay per HIV case detected. For 
example, the probability of being a cost-effective option 
for mobile-based VCT was about 10% at a willingness-to-
pay threshold of USD 220, while at a willingness-to-pay 
threshold of USD 260, the probability of the mobile-
based VCT being a cost-effective option was about 90% 
(Fig. 5).
Discussion
This study is the first of its kind in Ethiopia to compare 
the cost-effectiveness of facility-based, stand-alone, and 
mobile-based voluntary counseling and testing.
Cost of the VCT models
The unit cost per client tested for HIV at the facility-
based VCT is USD 5.06. Our finding of cost per client 
tested using a facility-based VCT is very comparable esti-
mated elsewhere. For example, a study in Malawi (USD 
5) and Zambia (USD 4), but substantially lower than 
the finding Zimbabwe (USD 9) [11]. Similarly, studies in 
Kenya and Swaziland in 2012 also reported that the unit 
cost of facility-based VCT ranges from USD 5.05 to 16 
and USD 8.6 to 19, respectively [12].
The cost per client tested for HIV for the stand-
alone-based VCT is USD 6.55 (3155 clients tested). 
Although the number of clients tested is higher than the 
Fig. 2 A tornado diagram
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facility-based VCT, the unit cost is higher due to how 
the project cost is implemented. The cost per client test 
of stand-alone-based VCT in this study varies dramati-
cally from other countries’ study reports. Studies of a 
systematic review of low and middle-income countries 
[13], South Africa [14], Uganda [15] Vietnam [16], and 
Namibia [17], showed the cost of stand-alone-based VCT 
estimated to be USD 20, 51, 19 and 58, and 60 per client 
tested respectively.
The cost per clients tested for HIV in a mobile-based 
VCT is USD 3.35 (8645 clients tested). The estimate of 
the cost per client through mobile-based VCT service 
under this study is lower than the cost estimate report 
in South Africa, Kenya, and Namibia with USD 25, 15, 
and 60 per client, respectively [17–19]. A systematic 
review conducted also estimated the cost per client test 
through mobile-based VCT to be USD 60 [20].
Fig. 3 One-way sensitivity analysis of the HIV positivity rate at mobile-based VCT
Fig. 4 Cost-effectiveness scatter plot
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The cost per HIV seropositive client of facility-based, 
stand-alone and mobile-based VCT is USD 158.82, 
150.97, and 135.52, respectively. The cost of HIV sero-
positive clients at a facility-based VCT is higher than 
in some study reports [11, 13, 15] and lower for study 
reports conducted in other countries [16, 17]. Some stud-
ies reports from other settings are comparable to our 
findings on the cost of HIV seropositive test for stand-
alone [16, 19] and mobile-based VCT [13, 19], although 
it varies in another study [17]. The variation in the unit 
costs among various studies might be partly attributed to 
the costing method applied, and the resources accounted 
in each of the studies, the difference in HIV prevalence 
in the area [13], organizational structure, economy of the 
country, and the level of encouragement of the popula-
tion to test for HIV which determines the level of econo-
mies of scale [31, 32].
This study is not without limitations. The measure of 
effectiveness is reported in intermediate outcomes with 
the number of clients tested and HIV seropositive iden-
tified. The use of intermediate outcome might pose dif-
ficulty compared with other interventions that are not 
reported with the same outcome measure. We did not 
use DALY measurement because of the lack of validated 
data on disability weights or one of the outcome meas-
ures. Since mobile-based VCT only performed in the 
year 2016, only a one-year data on clients were used for 
the three models. Some cost information was not avail-
able for the year the items were bought. To fill this gap, 
we estimated the costs by using the current market price 
of the items. A common denominator of the expected 
number of services provided at a health center is used for 
both stand-alone and mobile-based VCT to calculate the 
probability of being tested. A similar denominator is used 
because there is no standard set to determine the number 
of populations expected to be served under stand-alone 
and mobile-based VCT. Our data do not inform about 
repeated testers and new testers, which might influence 
the result if there is a repeated test for those HIV positive 
clients who knew their HIV status.
Cost‑effectiveness of the VCT models
Among the three models, stand-alone-based VCT was 
extendedly dominated by a linear combination of facility-
based and mobile-based VCT. Therefore, it was excluded 
from the further calculation of the incremental cost-
effectiveness ratios. We found that the incremental cost 
of mobile-based VCT to identify one more HIV sero-
positive client was USD 239 compared with facility-based 
VCT. Therefore, this study suggests that more HIV posi-
tive cases can be identified through a mobile-based VCT 
if some additional resources can be allocated to imple-
ment a mobile-based VCT service.
Currently, in Ethiopia, about 28% of the populations 
who are infected with the virus do not know their HIV 
status. The prevalence of HIV in an urban area is higher 
than the rural area, and it is known that the mobile-based 
VCT services are suited to highly populated areas [9, 
20]. Providing VCT through mobile-based service can 
decrease the number of HIV positive individuals who do 
not know their HIV status, and therefore, can decrease 
the transmission of the virus. Besides, it will help to 
Fig. 5 Cost-effectiveness acceptability curve
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achieve the UNAIDS 90-90-90 target that infected indi-
viduals who do know their status are more likely to start 
ART early [4]. Other studies elsewhere, such as South 
Africa and Kenya, recommend that mobile-based VCT 
can be an essential and cost-effective approach in addi-
tion to the facility-based approach [18, 19].
The ICER of mobile-based VCT remains stable in all 
sensitivity analysis for the selected parameters. The ICER 
was similar to the base case result in lower and higher 
values and the changing distributions. The one-way sen-
sitivity analysis indicated that as the prevalence of HIV 
increases, the mobile-based VCT would give more value 
for money. As the prevalence of HIV is 4.9% in Addis 
Ababa and other major cities, testing through mobile-
based VCT can be a big opportunity [3]. Besides, the cit-
ies are relatively densely populated, and this makes them 
more suited for mobile-based testing [9, 20].
The probabilistic sensitivity analysis indicates that the 
incremental net monetary benefit of providing mobile-
based VCT over the facility-based VCT increases linearly 
as the willingness to pay rises above USD 239. A recent 
report from UNAIDS indicates that about USD 6 billion 
is still needed to achieve the 90-90-90 goal. Supporting 
HIV prevention activities in developing countries is a 
continuous process, not a one-time action to eliminate it. 
In Ethiopia, the distribution of HIV is highly prevalent in 
urban areas. Interventions for a target population, such 
as female sex workers, are also made. Although this is a 
crucial step towards reducing transmission of the virus, 
HIV testing through the most efficient ways, such as the 
mobile-based VCT, is mandatory to reduce the overall 
prevalence in urban communities with a higher number 
of FSWs.
Conclusion
Using a mobile-based VCT approach costs less than both 
the facility-based and stand-alone approaches in terms 
of unit cost per tested individual and unit cost per HIV 
seropositive cases. Stand-alone-based VCT was extend-
edly dominated by a combination of facility-based and 
mobile-based VCT approaches, and therefore, was not 
cost-effective. The incremental cost-effectiveness ratio 
for mobile-based VCT compared with facility-based 
VCT was USD 239 per HIV positive case identified.
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